Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Cyclophosphamide 25Rituximab 22fludarabine 14Lenalidomide 10Vincristine 8Doxorubicin 8Prednisone 7Etoposide 7fludarabine phosphate 6Immunotherapy, Adoptive 5polatuzumab vedotin 4Cytarabine 4CT-P10 4Bendamustine Hydrochloride 4Antigens, CD19 4tocilizumab 3Gemcitabine 3Dexamethasone 3Carboplatin 3venetoclax 2veltuzumab 2prednylidene 2ofatumumab 2obinutuzumab 2ixazomib 2ibrutinib 2etoposide phosphate 2deltacortene 2carmustine, poliferprosan 20 drug combination 2acalabrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, B-Cell × Inotuzumab Ozogamicin × Clear all
NCT00299494 2018-03-08

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Pfizer

Phase 1/2 Completed
119 enrolled 60 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡